-+ 0.00%
-+ 0.00%
-+ 0.00%

Humacyte Realigns Ex-U.S. Rights To Symvess By Amending Its Distribution Deal With Fresenius Medical Care

Benzinga·04/24/2026 12:07:43
Listen to the news

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius Medical Care (FME).